Search

Boehringer Ingelheim annouces 2020 BVDzero Case Awards

Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.

Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry

Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being

Boehringer Ingelheim announces 2018 BVDzero Case Awards

Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

Boehringer Ingelheim Second Transforming Science Day

World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio

Partnership for new liver disease treatments with Ribo

Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Drug Discovery at Boehringer Ingelheim

Find out more about the drug discovery process at Boehringer Ingelheim

Acquisition expands research in cancer immunology

Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.

Sustainable Development

The Boehringer Ingelheim Veterinary Scholars Program

The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research

Revolutionizing drug development

Our scientists are leveraging the "digital twins"-technology to revolutionize biotherapeutic drug development.

Classical Swine Fever live vaccine approved in China

Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved

Boehringer receives SBTi validation for CO2 reduction targets

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

Boehringer Ingelheim China for a green future

Boehringer Ingelheim China for a green future: China employees were collecting trash on Nanhui Zui Beach for a greener future

License to develop new fibro-inflammatory disease treatments

Quality

At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.

Award: Boehringer Ingelheim is Global Top Employer 2022

Global Top Employer 2022

BI_X_Shanghai

Boehringer Ingelheim opens a second branch of its digital lab in Shanghai

"To join Boehringer Ingelheim was the best ever decision"

Pharmacologist Michael Mark worked for us for 34 years. He played a key role in the research and development of several medications. Watch our video and discover our job opportunities.

Phase 1 start for novel triple agonist obesity treatment

Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment

New Partnership to Develop Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis

Boehringer Ingelheim reaches more patients than ever, innovation drives growth

Boehringer Ingelheim reports a strong performance in 2022.

Boehringer Ingelheim 2022 half year results

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers